Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL2161470 | 0.88 | FFAR3 (0.39) | FFAR3LCKFYN | |
| Acetic Acid SCHEMBL8167089 | 0.86 | FFAR3 (0.37) | FFAR3LCKFYNTRPA1TSHR | |
| Acetic Acid SCHEMBL2166181 | 0.86 | FFAR3 (0.37) | FFAR3LCKFYNTGFBR1CHRM1 | |
| Acetic Acid SCHEMBL2166856 | 0.84 | FFAR3 (0.35) | FFAR3LCKFYNALDH1A1TDP1 | |
| Acetic Acid SCHEMBL2166044 | 0.82 | FFAR3 (0.33) | FFAR3LCKFYN | |
| Acetic Acid SCHEMBL11699356 | 0.80 | FFAR3 (0.78) | FFAR3LCKFYNALDH1A1LMNA | |
| Propionic Acid SCHEMBL577043 | 0.80 | FFAR3 (0.62) | FFAR3ALDH1A1TDP1KDM4EHPGD | |
| Acetic Acid SCHEMBL28275680 | 0.77 | — | — | |
| Acetic Acid SCHEMBL28252786 | 0.77 | — | — | |
| Acetic Acid SCHEMBL1409006 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6156692-A | Ruthenium-containing catalyst composition for olefin metathesis | BP AMOCO CORPORATION (US) | 2000-12-05 | — | — | US | claimed |
| US-8383274-B2 | Nonaqueous electrolyte solution for lithium battery, lithium battery using same, and formyloxy group-containing compound used therein | UBE INDUSTRIES, LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110183199-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN | UBE INDUSTRIES, LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| EP-1585743-B1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
| US-7053107-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1585743-A1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004056806-A1 | 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES | PFIZER INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| EP-0841988-B1 | A RUTHENIUM-BASED CATALYST COMPOSITION FOR OLEFIN METATHESIS | BP CORP NORTH AMERICA INC (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-0857183-B1 | PROCESS FOR PREPARATION OF ADDITION PRODUCTS OF DIFUNCTIONAL TELECHELIC POLYOLEFINS FROM CYCLIC OLEFINS BY OLEFIN METATHESIS REACTION | CALIFORNIA INST OF TECHN (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6159890-A | Ruthenium-containing catalyst system for olefin metathesis | BP AMOCO CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6156692-A | Ruthenium-containing catalyst composition for olefin metathesis | BP AMOCO CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| US-6143851-A | Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction | BP AMOCO CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6060570-A | Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction | BP AMOCO CORPORATION (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1999022866-A1 | A RUTHENIUM-CONTAINING CATALYST SYSTEM FOR OLEFIN METATHESIS | BP AMOCO CORPORATION (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0857183-A1 | PROCESS FOR PREPARATION OF ADDITION PRODUCTS OF DIFUNCTIONAL TELECHELIC POLYOLEFINS FROM CYCLIC OLEFINS BY OLEFIN METATHESIS REACTION | AMOCO CORPORATION (US) | 1998-08-12 | — | — | EP | disclosed |
| EP-0841988-A1 | A RUTHENIUM-BASED CATALYST SYSTEM FOR OLEFIN METATHESIS | AMOCO CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1998006771-A1 | PROCESS FOR PREPARATION OF ADDITION PRODUCTS OF DIFUNCTIONAL TELECHELIC POLYOLEFINS FROM CYCLIC OLEFINS BY OLEFIN METATHESIS REACTION | AMOCO CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997040934-A1 | A RUTHENIUM-BASED CATALYST SYSTEM FOR OLEFIN METATHESIS | AMOCO CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183199-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN | HCN2, KCNN2, KCNB1 | FFAR3 996/4885LCK 455/4885FYN 481/4885 |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | FFAR3 1693/4885LCK 44/4885FYN 125/4885 |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | FFAR3 1693/4885LCK 44/4885FYN 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.